The Top 5 Biosimilar Articles for the Week of February 15

Here are the top 5 biosimilar articles for the week of February 15, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of February 15, 2021.

Number 5: Lannett and HEC Pharm are developing an insulin aspart biosimilar on the heels of their insulin glargine codevelopment project.

Number 4: Biosimilars, supply chain adjustments, building trust, and international standardization were discussed during an international panel of government and industry experts as means to deliver innovation when it's needed, not after.

Number 3: Patients’ demographics and physiological characteristics influence whether they will accept a switch from an originator drug to a biosimilar, according to findings from a New Zealand study.

Number 2: Sandoz Canada said it has launched an adalimumab injectable biosimilar, which is indicated for 9 of the 12 conditions of the originator product (Humira).

Number 1: Celltrion Healthcare has gained EU marketing authorization for the first high-concentration, citrate-free adalimumab biosimilar.

To read all of these articles and more, visit centerforbiosimilars.com.